<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="./PMC7017508/results/search/disease/results.xml">
  <result pre="Article Annual and seasonal patterns in etiologies of pediatric community-acquired" exact="pneumonia" post="due to respiratory viruses and Mycoplasma pneumoniae requiring hospitalization"/>
  <result pre="available in this article, unless otherwise stated. Abstract Background Community–acquired" exact="pneumonia" post="(CAP) is one of the leading worldwide causes of"/>
  <result pre="at 23 nationwide hospitals in South Korea. Mycoplasma pneumoniae (MP)" exact="pneumonia" post="was clinically classified as macrolide-sensitive MP, macrolide-less effective MP"/>
  <result pre="identified pathogens of CAP. With the two epidemics of MP" exact="pneumonia" post="(2011 and 2015), the rates of clinical MLEP and"/>
  <result pre="(2011 and 2015), the rates of clinical MLEP and MRMP" exact="pneumonia" post="showed increasing trends of 36.4% of the total MP"/>
  <result pre="pediatric morbidity, requiring hospitalization, and mortality [ 1, 2]. Childhood" exact="pneumonia" post="causes diverse long-term sequelae, such as restrictive or obstructive"/>
  <result pre="pneumonia causes diverse long-term sequelae, such as restrictive or obstructive" exact="lung disease," post="as well as bronchiectasis, particularly in a considerable proportion"/>
  <result pre="in a considerable proportion of children hospitalized due to community-acquired" exact="pneumonia" post="(CAP) [ 3]. The etiologies of CAP affect the"/>
  <result pre="was in 2015 [ 7– 9]. After 2000, macrolide-resistant MP" exact="pneumonia" post="rapidly emerged, especially in Asia [ 7]. MP infections"/>
  <result pre="children are often self-limiting, even in patients with macrolide-resistant MP" exact="pneumonia" post="[ 10]. More than 80% of patients with macrolide-sensitive"/>
  <result pre="this occurs in approximately 30% of patients with macrolide-resistant MP" exact="pneumonia" post="[ 11]. Despite its high prevalence, large-scale epidemiologic studies"/>
  <result pre="Despite its high prevalence, large-scale epidemiologic studies of macrolide-resistant MP" exact="pneumonia" post="are scarce. In the present study, we aimed to"/>
  <result pre="in pediatric CAP requiring hospitalization and the prevalence of MP" exact="pneumonia" post="according to the clinical responses to macrolides. In addition,"/>
  <result pre="pediatricians based on both physical examinations and radiologic assessments. MP" exact="pneumonia" post="was defined as meeting at least one of the"/>
  <result pre="convalescent stages [ 8, 12]. The clinical courses of MP" exact="pneumonia" post="have shown heterogeneous features, even in patients with the"/>
  <result pre="clinical, laboratory, and radiologic features between children with macrolide-resistant MP" exact="pneumonia" post="and those with MSMP pneumonia [ 7– 9]. In"/>
  <result pre="between children with macrolide-resistant MP pneumonia and those with MSMP" exact="pneumonia" post="[ 7– 9]. In the present study, MP susceptibility"/>
  <result pre="were not performed. Instead, to characterize the clinically heterogeneous MP" exact="pneumonia" post="into more homogenous clinical groups, we defined clinical MSMP,"/>
  <result pre="clinical MSMP, macrolide-refractory MP (MRMP), and macrolide less-effective MP (MLEP)" exact="pneumonia" post="according to fever duration in each pneumonia episode after"/>
  <result pre="less-effective MP (MLEP) pneumonia according to fever duration in each" exact="pneumonia" post="episode after the initiation of macrolides, regardless of the"/>
  <result pre="respiratory viruses were as follows: adenovirus (AdV), human rhinovirus (HRV)," exact="influenza" post="virus (FLU), parainfluenza virus (PIV), human metapneumovirus (HMPV), respiratory"/>
  <result pre="analyses were used to examine if the characteristics of MP" exact="pneumonia" post="groups were statistically significant with the chi-squared test. For"/>
  <result pre="August). Table 1 Demographic characteristics of hospitalized children with community-acquired" exact="pneumonia" post="Variables No. (%) or mean ± SD Number 30,994 Age (mo),"/>
  <result pre="Figure S1). Fig. 1 Number of children hospitalized with community-acquired" exact="pneumonia" post="according to etiology between 2011 and 2015 in Korea"/>
  <result pre="Korea Fig. 2 Number of children hospitalized with community acquired" exact="pneumonia" post="according to etiology The two epidemics of MP pneumonia"/>
  <result pre="acquired pneumonia according to etiology The two epidemics of MP" exact="pneumonia" post="(2011 and 2015) corresponded with the two peaks of"/>
  <result pre="with the two peaks of CAP. The incidence of MP" exact="pneumonia" post="requiring hospitalization in children peaked from October to November"/>
  <result pre="year (Fig. 1). The most common clinical phenotype of MP" exact="pneumonia" post="was MSMP, followed by MLEP and MRMP (Fig. 3a)."/>
  <result pre="During the study period, the monthly rate of MSMP/total MP" exact="pneumonia" post="was 63.6–100.0% (mean ± SD, 81.3 ± 7.7), that of MRMP/total MP pneumonia"/>
  <result pre="MP pneumonia was 63.6–100.0% (mean ± SD, 81.3 ± 7.7), that of MRMP/total MP" exact="pneumonia" post="was 0.0–11.0% (4.2 ± 4.3), and that of MLEP/total MP pneumonia"/>
  <result pre="MP pneumonia was 0.0–11.0% (4.2 ± 4.3), and that of MLEP/total MP" exact="pneumonia" post="was 0.0–30.3% (14.5 ± 14.2) (Fig. 3b). The rates of clinical"/>
  <result pre="(14.5 ± 14.2) (Fig. 3b). The rates of clinical MLEP and MRMP" exact="pneumonia" post="showed increasing trends (seasonal Mann-Kendall trend tests, P = 0.0644 and"/>
  <result pre="P = 0.0644 and P = 0.0066, respectively), whereas the rates of clinical MSMP" exact="pneumonia" post="showed a significant reduction during the study period (seasonal"/>
  <result pre="the numbers of children hospitalized due to Mycoplasma pneumoniae (MP)" exact="pneumonia" post="according to clinical macrolide sensitivity. a Number of children"/>
  <result pre="clinical macrolide sensitivity. a Number of children hospitalized with MP" exact="pneumonia" post="classified as macrolide-sensitive (MSMP), macrolide-refractory (MRMP), and macrolide less-effective"/>
  <result pre="MP pneumonia, MRMP pneumonia/total MP pneumonia, and MLEP pneumonia/total MP" exact="pneumonia" post="during the study period Causative pathogens of CAP according"/>
  <result pre="age exhibited MP infections. The rate of clinical MRMP/total MP" exact="pneumonia" post="was highest in children 5–9 years of age (244/3475, 9.8%),"/>
  <result pre="according to age groups in children hospitalized due to community-acquired" exact="pneumonia" post="Detected respiratory virus &amp;lt; 2 years, No. (%) 2–4 years, No. (%)"/>
  <result pre="Systemic corticosteroids were most commonly administered to those with MP" exact="pneumonia" post="(1645/7455, 22.1%), followed by RSV pneumonia (622/4521, 13.8%). The"/>
  <result pre="to those with MP pneumonia (1645/7455, 22.1%), followed by RSV" exact="pneumonia" post="(622/4521, 13.8%). The number of children with CAP who"/>
  <result pre="who required oxygen supplementation was greatest in children with RSV" exact="pneumonia" post="(905/4521, 20.0%); ventilator care was most commonly applied in"/>
  <result pre="ventilator care was most commonly applied in children with AdV" exact="pneumonia" post="(13/680, 1.9%), followed by those with RSV pneumonia (119/4521,"/>
  <result pre="with AdV pneumonia (13/680, 1.9%), followed by those with RSV" exact="pneumonia" post="(119/4521, 2.6%). Table 3 Comparison of clinical and laboratory"/>
  <result pre="according to respiratory pathogens in children hospitalized due to community-acquired" exact="pneumonia" post="Variables only MP 1 ( n = 7455) MP coinfected with"/>
  <result pre="2, MP co-infected with virus; group 3, adenovirus; group 4," exact="influenza" post="virus; group 5, Metapneumovirus; group 6, RSV; The inequality"/>
  <result pre="analyses were used to examine if the characteristics of MP" exact="pneumonia" post="groups were statistically significant with chi-squared test. For the"/>
  <result pre="October–November and November–December, respectively. There were two epidemics of MP" exact="pneumonia" post="(2011 and 2015) during the study period. In children"/>
  <result pre="comprising up to 36% of the total cases of MP" exact="pneumonia" post="during the study period. In children less than 2 years"/>
  <result pre="problematic in infants, who are most frequently affected by RSV" exact="pneumonia" post="[ 15]. These findings may be valuable to guide"/>
  <result pre="due to CAP. The number of children hospitalized with MP" exact="pneumonia" post="was typically highest between October and November. In the"/>
  <result pre="November. In the previous studies, the peak incidence of MP" exact="pneumonia" post="showed a similar pattern to that observed in the"/>
  <result pre="Korean epidemic, the peak rate of hospitalization due to MP" exact="pneumonia" post="in children occurred in September, whereas the peak rate"/>
  <result pre="November. In addition, the number of children hospitalized with MP" exact="pneumonia" post="in the 2015 epidemic was smaller than that in"/>
  <result pre="vitro macrolide sensitivity tests, the macrolide resistance rates of MP" exact="pneumonia" post="have recently been identified as 50–90% in Asia ["/>
  <result pre="to fever duration after the initiation of macrolides in each" exact="pneumonia" post="episode, regardless of the results of in vitro macrolide"/>
  <result pre="the ratios of clinical MLEP and MRMP of total MP" exact="pneumonia" post="showed increasing trends after adjustment for monthly time series."/>
  <result pre="for monthly time series. However, the estimated clinical MRMP/total MP" exact="pneumonia" post="ratio during the study period in the present study"/>
  <result pre="study suggest that the clinical response to macrolides in MP" exact="pneumonia" post="in the real world might not be as weak"/>
  <result pre="respect to clinical and radiologic findings between MRMP and MSMP" exact="pneumonia" post="in children [ 8, 9]. When combined with the"/>
  <result pre="8, 13], a considerable proportion of cases of macrolide-resistant MP" exact="pneumonia" post="might be recategorized as clinical MSMP or MLEP pneumonia."/>
  <result pre="MSMP or MLEP pneumonia. Therefore, the first-line treatment for MP" exact="pneumonia" post="can be initially started, even in cases of MRMP"/>
  <result pre="pneumonia. Considering the exaggerated immune response in children with MP" exact="pneumonia" post="[ 18], the application of immune-modulators, such as corticosteroids"/>
  <result pre="MP pneumonia, even in some cases of MLEP or MRMP" exact="pneumonia" post="[ 19]. When selecting the proper treatment strategy for"/>
  <result pre="some patients might have been misclassified into the &quot;no MP" exact="pneumonia" post="and no respiratory virus detection&quot; group due to a"/>
  <result pre="the introduction of the pneumococcal conjugate vaccine and the Haemophilus" exact="influenza" post="type b vaccine, the disease burden due to bacterial"/>
  <result pre="Haemophilus influenza type b vaccine, the disease burden due to" exact="bacterial pneumonia" post="has been significantly decreased [ 6, 20]. Therefore, we"/>
  <result pre="influenza type b vaccine, the disease burden due to bacterial" exact="pneumonia" post="has been significantly decreased [ 6, 20]. Therefore, we"/>
  <result pre="20]. Therefore, we clinically defined the MSMP, MRMP, and MLEP" exact="pneumonia" post="groups solely based on fever duration after initiation of"/>
  <result pre="might play more important roles in the treatment of MP" exact="pneumonia" post="in some cases, the application of clinical classifications of"/>
  <result pre="LINK Additional file 1: Figure S1. Time-dependent trends of community-acquired" exact="pneumonia" post="due to various respiratory viruses. (A) Influenza. (B) Adenovirus."/>
  <result pre="(D) Parainfluenza. Abbreviations AdV Adenovirus BoV Bocavirus CAP Community acquired" exact="pneumonia" post="FLU Influenza virus HCoV Human coronavirus HMPV Human metapneumovirus"/>
  <result pre="O'Brien KL Campbell H Black RE Global burden of childhood" exact="pneumonia" post="and diarrhoea Lancet 2013 381 9875 1405 1416 10.1016/S0140-6736(13)60222-6"/>
  <result pre="C Anderson EJ Grijalva CG Self WH et al. Community-acquired" exact="pneumonia" post="requiring hospitalization among U.S. children N Engl J Med"/>
  <result pre="J Prevalence and clinical manifestations of macrolide resistant mycoplasma pneumoniae" exact="pneumonia" post="in Korean children Korean J Pediatr 2017 60 5"/>
  <result pre="Choung JT Macrolide resistance and its impacts on M. pneumoniae" exact="pneumonia" post="in children: comparison of two recent epidemics in Korea"/>
  <result pre="findings and clinical features in hospitalized children with mycoplasma pneumoniae" exact="pneumonia" post="PLoS One 2019 14 8 e0219463 10.1371/journal.pone.0219463 31461462 13."/>
  <result pre="RE Campbell H et al. Epidemiology and etiology of childhood" exact="pneumonia" post="in 2010: estimates of incidence, severe morbidity, mortality, underlying"/>
  <result pre="Z Cytokines as the good predictors of refractory mycoplasma pneumoniae" exact="pneumonia" post="in school-aged children Sci Rep 2016 6 37037 10.1038/srep37037"/>
  <result pre="JH Effects of methylprednisolone pulse therapy on refractory mycoplasma pneumoniae" exact="pneumonia" post="in children Allergy, Asthma Immunol Res 2014 6 1"/>
 </snippets>
</snippetsTree>
